Innovations In Clinical Neuroscience

JAN-FEB 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 28 of 63

[ V O L U M E 1 4 , N U M B E R 1 – 2 , J A N U A R Y – F E B R U A R Y 2 0 1 7 ] Innovations in CLINICAL NEUROSCIENCE 29 …/Guidances/UCM338287.pdf. Accessed February 2017. 48. Kozauer N, Katz R. Regulatory innovation and drug development for early stage Alzheimer's disease. N Engl J Med. 2013;368:1169–1171. 49. European Medicines Agency [website]. Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. 15 March 2012. docs/en_GB/document_library/Scientific _guideline/2012/03/WC500124534.pdf. Accessed February 2017. 50. European Medicines Agency [website]. Concept paper on need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. 24 October 2013. document_library/Scientific_guideline/20 13/10/WC500153464.pdf. Accessed February 2017. 51. European Medicines Agency [website]. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. 28 January 2016. docs/en_GB/document_library/Scientific _guideline/2016/02/WC500200830.pdf. Acessed February 2017. 52. Green Park Collaborative. Center for Medical Technology Policy [website]. Evidence Guidance Document: Alzheimer's Disease. April 2013. GPC_Evidence_Guidance_Document_- _Alzheimers_Disease.pdf Accessed April 29, 2016. 53. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19:448–450. 54. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356–1364. 55. Hendrix SB. Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. Alzheimers Res Ther. 2012;4:24. 56. Karin A, Hannesdottir K, Jaeger J, et al. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response. Acta Neurol Scand. 2014;129:114–122. 57. Langbaum JB, Hendrix SB, Ayutyanont N, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement. 2014;10:666–674. 58. Raghavan N, Samtani MN, Farnum M, et al. The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement. 2013;9:S21–S31. 59. Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatry. 2016;87(9):993–999. Epub 2016 Mar 23. 60. Skinner J, Carvalho JO, Potter GG, et al. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012;6:489–501. 61. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66. 62. Sano M, Raman R, Emond J, et al. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25:122–127. 63. Doraiswamy PM, Bieber F, Kaiser L, et al. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology. 1997;48:1511–1517. 64. Hobart J, Cano S, Posner H, et al. Putting the Alzheimer's cognitive test to the test. I: traditional psychometric methods. Alzheimers Dement. 2013;9:S4–9. 65. Hobart J, Cano S, Posner H, et al. Putting the Alzheimer's cognitive test to the test. II: Rasch Measurement Theory. Alzheimers Dement. 2013;9:S10–20. 66. Andrich D. Rating scales and Rasch measurement. Expert Rev Pharmacoecon Outcomes Res. 2011;11:571–585. 67. O'Bryant SE, Lacritz LH, Hall J, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol. 2010;67:746– 749. 68. Coley N, Andrieu S, Jaros M, et al. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimers Dement. 2011;7:602– 610 e602. 69. Balsamo M, Giampaglia G, Saggino A. Building a new Rasch-based self-report inventory of depression. Neuropsychiatr Dis Treat. 2014;10:153–165. 70. Borsboom D. The attack of the psychometricians. Psychometrika. 2006;71:425–440. 71. Ard MC, Galasko DR, Edland SD. Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale. Alzheimer Dis Assoc Disord. 2013;27:187–191. 72. Mungas D, Crane PK, Gibbons LE, et al. Advanced psychometric analysis and the Alzheimer's Disease Neuroimaging Initiative: reports from the 2011 Friday Harbor conference. Brain Imaging Behav. 2012;6:485–488. 73. Vellas B, Bateman R, Blennow K, et al. Endpoints for pre-dementia AD trials: a report from the EU/US/CTAD task force. J Prev Alzheimers Dis. 2015;2:128–135. 74. Ard MC, Raghavan N, Edland SD. Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharm Stat. 2015;14:418–426.

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - JAN-FEB 2017